A Case Report of MPO-ANCAAssociated Vasculitis Following Heterologous mRNA1273 COVID-19Booster Vaccination
Journal of Korean Medical Science
; : e204-2022.
Article
en En
| WPRIM
| ID: wpr-938040
Biblioteca responsable:
WPRO
ABSTRACT
Despite that clinical trials have been examining the safety profile of coronavirus disease 2019 (COVID-19) vaccines, there are concerns about long-term side effects as the number of vaccinations increases. Herein, we report a case of new-onset renal-limited antimyeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis after booster vaccination with the mRNA 1273 (Moderna) vaccine. A 72-year-old woman with no specific past history, and who had a normal renal function, developed ANCAassociated vasculitis following heterologous booster with mRNA1273 (Moderna) vaccine.After a kidney biopsy, she was diagnosed with ANCA-associated pauci-immune crescentic glomerulonephritis. Her renal function and constitutional symptoms have been improved with treatment with plasmapheresis, intravenous cyclophosphamide and steroid pulse therapy (intravenous 500 mg of methylprednisolone sodium succinate for 3 days) followed by a reduced steroid regimen.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Journal of Korean Medical Science
Año:
2022
Tipo del documento:
Article